Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Cboe UK CHF

Santhera Pharmaceuticals Holding AG (SANNZ.XC)

Compare
16.26
-0.32
(-1.93%)
At close: February 28 at 4:19:12 PM GMT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.
NameTitlePayExercisedYear Born
Dr. Thomas Meier Ph.D. Founder & Chairman 100k -- 1962
Mr. Dario Eklund Chief Executive Officer 1M -- 1968
Mr. Marc Schrader Chief Technology Officer -- -- --
Dr. Oliver P. Kronenberg Chief Legal Officer & Corporate Secretary -- -- --
Mr. Neville Kodkani M.D. Head of Global Marketing & Partner Management -- -- --
Ms. Sarah Holmes-Klotz Head of People & Culture -- -- --
Mr. Andreas Missy Executive Vice President of Corporate Planning & Business Development -- -- --
Mr. Geert Jan van Daal M.D., Ph.D. Chief Commercial Officer -- -- --
Ms. Ana de Vera M.D. Head of Development & Deputy CMO -- -- --

Santhera Pharmaceuticals Holding AG

Hohenrainstrasse 24
Pratteln, 4133
Switzerland
41 61 906 89 50 https://www.santhera.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
44

Description

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Corporate Governance

Santhera Pharmaceuticals Holding AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

April 23, 2025 at 10:59 AM UTC - April 28, 2025 at 12:00 PM UTC

Santhera Pharmaceuticals Holding AG Earnings Date

Recent Events